Peer-reviewed veterinary case report
Gamma-vinyl-gamma-aminobutyric acid for epilepsy control in dogs
By Speciale, J et al.·Published in Journal of the American Veterinary Medical Association·1991·Department of Clinical Studies, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical evaluation of gamma-vinyl-gamma-aminobutyric acid for control of epilepsy in dogs.
- Species:
- dog
Plain-English summary
A group of 14 dogs with epilepsy that wasn't well controlled by standard medications were given a new drug called gamma-vinyl-gamma-aminobutyric acid along with their usual treatments. Out of these dogs, four showed a noticeable decrease in seizure frequency, while four others did not respond better than just using phenobarbital alone. In two dogs, the new drug helped with seizure control, but it had to be stopped due to a serious side effect called hemolytic anemia, where red blood cells are destroyed. This small study highlights the challenges in finding effective treatments for dogs with difficult-to-manage seizures.
People also search for: dog epilepsy treatment · new medication for dog seizures · gamma-vinyl-gamma-aminobutyric acid for dogs · phenobarbital alternatives for dogs
Abstract
Gamma-vinyl-gamma-aminobutyric acid is a novel antiepileptic drug that exerts its effects by increasing the concentration of gamma-aminobutyric acid in the brain. The mechanism of action involves irreversible inhibition of the metabolic pathway of gamma-aminobutyric acid. The drug was administered to 14 dogs in conjunction with other anticonvulsants, in an attempt to control refractory epilepsy. Four of these dogs had clinically relevant evidence of decreased seizure frequency. In 4 dogs, response to the drug was no better than response to phenobarbital alone. In 2 dogs, seizure control improved, but gamma-vinyl-gamma-aminobutyric acid was withdrawn because of development of hemolytic anemia. For various reasons, the therapeutic effect in the remaining 4 dogs could not be evaluated. This study of only 14 dogs illustrates some of the problems that confound our ability to judge the efficacy of anticonvulsant treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/2032927/